Matching articles for "leucovorin"
Issue 1754 · May 11, 2026
Leucovorin for Cerebral Folate Deficiency

The FDA has approved use of oral leucovorin calcium (folinic acid) for treatment of cerebral folate transport deficiency in patients who have a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD). It…

Med Lett Drugs Ther. 2026 May 11; 68(1754):75-7 doi:10.58347/tml.2026.1754b
The FDA has approved use of oral leucovorin calcium (folinic acid) for treatment of cerebral folate transport deficiency in patients who have a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD). It is the first drug to be approved for this extremely rare disorder.
Issue 1717 · December 9, 2024
Zolbetuximab (Vyloy) for Gastric and Gastroesophageal Carcinoma (online only)

Zolbetuximab-clzb ( Vyloy – Astellas), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, has been approved by the FDA for use in combination with fluoropyrimidine- and platinum-containing chemotherapy…

Med Lett Drugs Ther. 2024 Dec 9; 66(1717):e204-5 doi:10.58347/tml.2024.1717g
Zolbetuximab-clzb ( Vyloy – Astellas), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, has been approved by the FDA for use in combination with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have CLDN18.2-positive tumors. It is the first monoclonal antibody to be approved in the US that selectively targets CLDN18.2.
Issue 1616 · January 25, 2021
Encorafenib (Braftovi) for Metastatic Colorectal Cancer

The FDA has approved the oral kinase inhibitor encorafenib ( Braftovi – Pfizer), in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux) , for treatment of adults with…

Med Lett Drugs Ther. 2021 Jan 25; 63(1616):15-6
The FDA has approved the oral kinase inhibitor encorafenib ( Braftovi – Pfizer), in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux) , for treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation. Encorafenib was approved in 2018 for use with the mitogen-activated kinase (MEK) inhibitor binimetinib (Mektovi) for treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Issue 1496 · June 6, 2016 Free
In Brief: Liposomal Irinotecan (Onivyde) for Pancreatic Cancer (online only)

A liposomal formulation of irinotecan ( Onivyde – Merrimack) has been approved by the FDA for use in combination with fluorouracil and leucovorin for treatment of metastatic pancreatic cancer that has…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):e76
A liposomal formulation of irinotecan ( Onivyde – Merrimack) has been approved by the FDA for use in combination with fluorouracil and leucovorin for treatment of metastatic pancreatic cancer that has progressed after gemcitabine-based therapy. A non-liposomal formulation of irinotecan ( Camptosar , and generics) has been available in the US for many years. The liposomal carrier prolongs exposure to irinotecan and improves the cellular uptake and cytotoxic effect of the drug. 1 FDA approval of liposomal irinotecan was based on the results of an open-label trial (NAPOLI-1) in 417 patients with metastatic pancreatic ductal adenocarcinoma whose disease progressed after gemcitabine-based therapy. Patients were randomized to receive either liposomal irinotecan alone, fluorouracil and leucovorin alone, or liposomal irinotecan in combination with fluorouracil and leucovorin. Median overall survival, the primary endpoint, was significantly longer with all three drugs (6.1 months), compared to fluorouracil and leucovorin alone (4.2 months) and liposomal irinotecan alone (4.9 months). The most frequent severe (grade 3 or 4) adverse effects of the liposomal irinotecan-containing regimen were neutropenia, diarrhea, vomiting, and fatigue. 2 Life-threatening diarrhea has also occurred in patients receiving the 3-drug combination. Onivyde is available in 43 mg/10 mL single-dose vials. The recommended dosage is 70 mg/m 2 administered intravenously over 90 minutes every 2 weeks; leucovorin and fluorouracil should be administered after liposomal irinotecan. The recommended starting dose of Onivyde for patients who are homozygous for the UGT1A1*28 allele is 50 mg/m 2 ; the dose can be increased to 70 mg/m 2 as tolerated. The labeling specifies a number of dosage adjustments that should be made when adverse effects occur. One dose of Onivyde costs $4860. 3 A Casadó et al. Formulation and in vitro characterization of thermosensitive liposomes for the delivery of irinotecan. J Pharm Sci 2014; 103:3127. A Wang-Gillam et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387:545. Approximate WAC for a patient with a 1.7 m 2 surface area. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. May 5, 2016. Reprinted with permission by First Databank, Inc. All rights reserved. ©2016. www.fdbhealth.com/policies/drug-pricing-policy. Download complete U.S. English article
Issue 48 · August 1, 2006
Chemotherapy for Esophageal, Gastric and Colorectal Cancers

A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and…

Treat Guidel Med Lett. 2006 Aug; 4(48):55-60
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Issue 1189 · August 16, 2004
Drugs for Parasitic Infections

Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously…

Med Lett Drugs Ther. 2004 Aug 16; 46(1189):66
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table below lists first-choice and alternative drugs for most parasitic infections. The brand names and manufacturers of the drugs are listed in this article.
Issue 1184 · June 7, 2004
Two New Drugs for Colon Cancer

Cetuximab ( Erbitux - ImClone Systems/Bristol-Myers Squibb), an epidermal growth factor receptor (EGFR) inhibitor, and bevacizumab ( Avastin - Genentech), the first vascular endothelial growth factor…

Med Lett Drugs Ther. 2004 Jun 7; 46(1184):46-8
Cetuximab ( Erbitux - ImClone Systems/Bristol-Myers Squibb), an epidermal growth factor receptor (EGFR) inhibitor, and bevacizumab ( Avastin - Genentech), the first vascular endothelial growth factor angiogenesis inhibitor, have recently been approved by the FDA for treatment of patients with metastatic colorectal cancer. Cetuximab is approved for treatment of patients with EGFR-expressing tumors, either in combination regimens with irinotecan ( Camptosar )when the cancer has progressed on irinotecan-based therapy, or as monotherapy for those who cannot tolerate irinotecan. Bevacizumab is approved for first-line therapy in combination with a fluorouracil-based regimen.
Issue 7 · March 1, 2003
Drugs of Choice for Cancer

The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants.…

Treat Guidel Med Lett. 2003 Mar; 1(7):41-52
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.
Issue 1148 · January 20, 2003
Oxaliplatin (Eloxatin) for Advanced Colon Cancer

Oxaliplatin ( Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil , and others) and leucovorin (LV; Wellcovorin ) for patients with metastatic…

Med Lett Drugs Ther. 2003 Jan 20; 45(1148):7-8
Oxaliplatin ( Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil , and others) and leucovorin (LV; Wellcovorin ) for patients with metastatic colorectal cancer whose disease has recurred or progressed despite treatment with 5-FU/LV plus irinotecan ( Camptosar - Medical Letter 1997; 39:8).
Issue 1141 · October 14, 2002
Generic drugs

When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the…

Med Lett Drugs Ther. 2002 Oct 14; 44(1141):89-90
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Issue 1127 · April 1, 2002
Drugs for Parasitic Infections

Superseded--purchase updated Parasitic Infections article Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS,…

Med Lett Drugs Ther. 2002 Apr 1; 44(1127):32
Superseded--purchase updated Parasitic Infections article Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. Note: Drugs for Parasitic Infections, revised and updated, is now available to both subscribers and nonsubscribers on our web site. This article, a bi-annual feature of The Medical Letter for many years, will not be published as a printed issue in 2002, but is included in the 16th edition of The Medical Letter Handbook of Antimicrobial Therapy. The handbook is now available and can be ordered by calling customer service at 1-800-211-2769.
Issue 1087 · September 18, 2000
Drugs of Choice For Cancer Chemotherapy (combined issue 1087-1088)

The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for…

Med Lett Drugs Ther. 2000 Sep 18; 42(1087):83-92
The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. For many of the cancers listed, surgery and/or radiation therapy are also part of the management of the disease.
Issue 1017 · January 2, 1998
Drugs for Parasitic Infections

(Superseded by the 2013 version. Click here to purchase. ) Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS,…

Med Lett Drugs Ther. 1998 Jan 2; 40(1017):1-12
(Superseded by the 2013 version. Click here to purchase. ) Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table lists first-choice and alternative drugs for most parasitic infections.
Issue 904 · September 3, 1993
Drugs for AIDS and Associated infections

Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with AIDS.

Med Lett Drugs Ther. 1993 Sep 3; 35(904):79-86
Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with AIDS.
Issue 855 · October 18, 1991
Drugs For AIDS And Associated Infections

A growing number of clinical trials now permits some consensus on the treatment of human immunodeficiency virus (HIV) and other infections associated with acquired immune deficiency syndrome (AIDS) in adults.

Med Lett Drugs Ther. 1991 Oct 18; 33(855):95-102
A growing number of clinical trials now permits some consensus on the treatment of human immunodeficiency virus (HIV) and other infections associated with acquired immune deficiency syndrome (AIDS) in adults.